Treatment reduced tissue triglycerides by 38% and macrovesicular steatosis by 40% over 6 hoursTreatment down-regulated the expression of markers for oxidative injury as well as activation of immune cells (CD14; CD11b) and reduced the release of inflammatory cytokines in the per- fusate (tumor necrosis factor α; interleukin 1β). Here, ITGAM is linked to steatosis.